BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Forecasted to Earn FY2025 Earnings of $1.98 Per Share

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a report issued on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of $1.98 for the year, down from their prior estimate of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The firm had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. During the same quarter last year, the business posted $0.11 earnings per share. The firm’s revenue was up 20.2% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Piper Sandler cut their target price on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Robert W. Baird cut their target price on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday, January 30th. Royal Bank of Canada reissued a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $91.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $107.61.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $88.63 on Thursday. The business has a fifty day moving average of $87.61 and a two-hundred day moving average of $89.12. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12. The stock has a market cap of $16.73 billion, a price-to-earnings ratio of 100.72, a price-to-earnings-growth ratio of 1.67 and a beta of 0.31. BioMarin Pharmaceutical has a 52-week low of $76.02 and a 52-week high of $99.56.

Insider Activity at BioMarin Pharmaceutical

In related news, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction on Friday, April 12th. The stock was sold at an average price of $91.26, for a total value of $1,825,200.00. Following the completion of the transaction, the director now directly owns 474,994 shares in the company, valued at $43,347,952.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at $1,454,040. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction on Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the completion of the transaction, the director now owns 474,994 shares of the company’s stock, valued at $43,347,952.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 103,229 shares of company stock worth $9,062,967. Company insiders own 1.84% of the company’s stock.

Institutional Trading of BioMarin Pharmaceutical

A number of institutional investors have recently bought and sold shares of the business. Stratos Wealth Partners LTD. lifted its holdings in BioMarin Pharmaceutical by 2.1% during the 4th quarter. Stratos Wealth Partners LTD. now owns 5,709 shares of the biotechnology company’s stock worth $550,000 after buying an additional 115 shares during the last quarter. CWM LLC lifted its holdings in BioMarin Pharmaceutical by 10.0% during the 3rd quarter. CWM LLC now owns 1,301 shares of the biotechnology company’s stock worth $115,000 after buying an additional 118 shares during the last quarter. KB Financial Partners LLC lifted its holdings in BioMarin Pharmaceutical by 51.3% during the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock worth $31,000 after buying an additional 118 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in BioMarin Pharmaceutical by 3.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,342 shares of the biotechnology company’s stock worth $322,000 after buying an additional 121 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in BioMarin Pharmaceutical by 0.4% during the 4th quarter. Howe & Rusling Inc. now owns 36,279 shares of the biotechnology company’s stock worth $3,755,000 after buying an additional 128 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.